Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.45 |
| ▸ | PDE4A | P27815 | 6/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.45 |
| ▸ | BRD4 | O60885 | 4/20 | 0.43 |
| ▸ | BRD2 | P25440 | 2/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11192985 | 0.81 | ALDH1A1 (0.54) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17622533 | 0.76 | KMT2A (0.51) | MEN1ALDH1A1KMT2A | |
| SCHEMBL30072152 | 0.73 | TP53 (0.50) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL30071733 | 0.73 | CYP11B1 (0.48) | ALDH1A1KMT2ASMN1; SMN2CNOT7 | |
| SCHEMBL30595217 | 0.72 | PARN (0.54) | BRD4SMN1; SMN2ADORA2BCNOT7 | |
| SCHEMBL30071914 | 0.71 | CYP11B2 (0.51) | MEN1ALDH1A1KMT2A | |
| SCHEMBL30072025 | 0.71 | ROCK2 (0.46) | — | |
| SCHEMBL30071806 | 0.71 | BRD4 (0.49) | BRD4BRD2BRD3BRDTMEN1 | |
| SCHEMBL30072037 | 0.70 | QPCT (0.42) | ADORA2AALDH1A1SMN1; SMN2ADORA1 | |
| SCHEMBL30072144 | 0.70 | DBH (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295879-A1 | NK1 Antagonists | OPKO HEALTH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8026364-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100190759-A1 | NK 1 ANTAGONISTS | OPKO HEALTH, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7709641-B2 | Neurokinin-1, substance P (NK1); serotonin reuptake inhibitors; for treating emesis, depression, anxiety and cough | OPKO HEALTH, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-4477442-A | PENTOFURANOSYL-5,6-DIHYDROTRIAZINES IN TREATMENT OF VIRAL DISEASES | THE UPJOHN COMPANY (US) | 1984-10-16 | — | — | US | disclosed |
| US-4423212-A | Nucleosides and process | THE UPJOHN COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
| US-4239753-A | Composition of matter and process | THE UPJOHN COMPANY (US) | 1980-12-16 | — | — | US | disclosed |
| US-4171431-A | Nucleosides and process | THE UPJOHN COMPANY (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190759-A1 | NK 1 ANTAGONISTS | BDKRB1, PROKR1, NPSR1 | ADORA2A 295/4885PDE4A 2570/4885PDE4B 2795/4885 |
| US-20120295879-A1 | NK1 Antagonists | NPSR1, GRPR, PROKR1 | ADORA2A 311/4885PDE4A 2047/4885PDE4B 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.